Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Viridian Therapeutics, Inc.\DE's total debt was $20.89M at Sep 30, 2025. For fiscal 2024 it was $20.58M, up 1.9% from the year before. The highest annual figure on record is $20.58M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $20.58M | +1.9% |
| FY2023 | Dec 31, 2023 | $20.21M | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $4.33M | -45.9% |
| FY2018 | Dec 31, 2018 | $8.00M | -19.3% |
| FY2017 | Dec 31, 2017 | $9.92M | +251.8% |
| FY2016 | Dec 31, 2016 | $2.82M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $20.89M | +1.8% |
| Q2 FY2025 | Jun 30, 2025 | $20.79M | +1.6% |
| Q1 FY2025 | Mar 31, 2025 | $20.69M | +2.4% |
| Q4 FY2024 | Dec 31, 2024 | $20.58M | – |
| Q3 FY2024 | Sep 30, 2024 | $20.52M | +397.3% |
| Q2 FY2024 | Jun 30, 2024 | $20.45M | +280.1% |
| Q4 FY2023 | Dec 31, 2023 | $20.21M | +496.2% |
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $4.13M | -21.5% |
| Q2 FY2020 | Jun 30, 2020 | $5.38M | -13.0% |
| Q1 FY2020 | Mar 31, 2020 | $3.39M | -52.2% |
| Q4 FY2019 | Dec 31, 2019 | $4.33M | -45.9% |
| Q3 FY2019 | Sep 30, 2019 | $5.26M | -41.0% |
| Q2 FY2019 | Jun 30, 2019 | $6.18M | -37.1% |
| Q1 FY2019 | Mar 31, 2019 | $7.09M | -29.2% |
| Q4 FY2018 | Dec 31, 2018 | $8.00M | -19.3% |
| Q3 FY2018 | Sep 30, 2018 | $8.91M | +540.8% |
| Q2 FY2018 | Jun 30, 2018 | $9.82M | +425.0% |
| Q1 FY2018 | Mar 31, 2018 | $10.02M | +326.8% |
| Q4 FY2017 | Dec 31, 2017 | $9.92M | +251.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.39M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.87M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.35M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.82M | – |
See a number that looks wrong?